摘要
Abstract
Objective To systemic evaluate the effectiveness and safety of canagliflozin in the treatment of patients with type 2 diabetes mellitus. Methods Computer retrieval PubMed, Cochrane Library, EMbase, CNKI, CBM and Wanfang database to find all of the randomized controlled trials ( RCTs) about the effectiveness and safety of canagliflozin and placebo in the treatment of type 2 diabetes, the retrieval time was from the establishment of database to April 8, 2015. References screen were performed manually. Meta-analysis was carried out using RevMan 5. 2 software, based on inclusion and exclusion criteria, the quality of the studies were analyzed by 2 reviewers. Results Finally 8 RCTs were included, Meta-analysis re-sults showed that:(1) Effectiveness:fasting blood glucose levels (MD= -1. 42, 95%CI-1. 87 ~ -0. 97, P <0. 01) , HbA1c level (MD= -0. 62, 95%CI -1. 07 ~ -0. 17, P <0. 01), body mass index (MD= -3. 01, 95%CI-4. 07 ~ -1. 95, P <0. 01) in the 2 groups showed statistically significant differences, canagliflozin group was better than the placebo group in reducing fasting blood glucose level, HbA1c level and body mass index. (2) Safety: canagliflozin group’ s urinary tract infection incidence was similar to the placebo group, the difference was not statistically significant (OR=1. 19, 95%CI 0. 74~1. 92, P >0. 05), canagliflozin group genital infection rate was significantly higher than that of the placebo group (OR=4. 07, 95%CI 2. 74 ~ 6. 02, P <0. 01). Conclusion Canagliflozin can effectively reduce fasting blood glucose, HbA 1c and body mass index in patients with type 2 diabetes, but increase the incidence of genital infection.关键词
坎格列净/2型糖尿病/钠-葡萄糖协同转运蛋白2 抑制剂/Meta分析Key words
Canagliflozin/Type 2 diabetes/Sodium glucose co-transporter 2 inhibitor/Meta-analysis
